Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Code

Type your Poster Code, then hit apply

Showing 1,267 results.

Thumbnail for Efficacy, Safety, and Resistance in Pirtobrutinib-Treated CLL/SLL After Covalent BTK Inhibitor Failure: A Systematic Review of the BRUIN Trial Program

CLL - 963

Efficacy, Safety, and Resistance in Pirtobrutinib-Treated CLL/SLL After Covalent BTK Inhibitor Failure: A Systematic Review of the BRUIN Trial Program

Kolluri Prathyusha

Poster Presenter: Kolluri Prathyusha

Thumbnail for Clinical and Prognostic Impact of CEBPA Mutations in Myelodysplastic Syndromes

MDS - 964

Clinical and Prognostic Impact of CEBPA Mutations in Myelodysplastic Syndromes

Mohamed M. Khamis

Poster Presenter: Mohamed M. Khamis

Previous 1...76 77 78 79 80 81 82...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

MM - 966

Safety Profile of Elotuzumab-Based Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

FNU Raja

Poster Presenter: FNU Raja

Thumbnail for Cardiovascular, Bleeding, and Mortality Outcomes with Acalabrutinib vs. Zanubrutinib in Chronic Lymphocytic Leukemia: A Real-World Analysis from the Epic Cosmos Federated EHR Network

CLL - 967

Cardiovascular, Bleeding, and Mortality Outcomes with Acalabrutinib vs. Zanubrutinib in Chronic Lymphocytic Leukemia: A Real-World Analysis from the Epic Cosmos Federated EHR Network

Abat Khan

Poster Presenter: Abat Khan

Thumbnail for Residual Excess Mortality During the COVID-19 Era in Multiple Myeloma and Related Plasma Cell Neoplasms: A CDC WONDER Counterfactual Predictive Analysis

MM - 968

Residual Excess Mortality During the COVID-19 Era in Multiple Myeloma and Related Plasma Cell Neoplasms: A CDC WONDER Counterfactual Predictive Analysis

Nanditha Karra

Poster Presenter: Nanditha Karra

Thumbnail for Treatment Response of Dasatanib in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients

CML - 969

Treatment Response of Dasatanib in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients

Baalamurugan K T

Poster Presenter: Baalamurugan K T

Thumbnail for Early Acute Kidney Injury and Mortality in Critically Ill Patients With Multiple Myeloma: A Two-Cohort Study

MM - 970

Early Acute Kidney Injury and Mortality in Critically Ill Patients With Multiple Myeloma: A Two-Cohort Study

Aroog Khaliq

Poster Presenter: Aroog Khaliq

Thumbnail for MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

AML - 971

MRD-Adjusted Therapeutic Index of Menin Inhibitors in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia: A Genotype-Stratified Systematic Review and Meta-Analysis

Sai Mourya Meda

Poster Presenter: Sai Mourya Meda

Thumbnail for A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept Versus Placebo in Patients With Myelofibrosis (MF) and Anemia on Concurrent Ruxolitinib Therapy: The ELRISE MF Study Design

MPN - 973

A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept Versus Placebo in Patients With Myelofibrosis (MF) and Anemia on Concurrent Ruxolitinib Therapy: The ELRISE MF Study Design

Pankit J Vachhani

Poster Presenter: Pankit J Vachhani

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors